Carrie Dougherty, MD, FAHS and Jessica Ailani, MD review migraine abstracts from the 2024 European Headache Congress.

A phase 3 study showed that combining pelabresib with ruxolitinib significantly improved spleen volume reduction and symptom relief in myelofibrosis patients compared to ruxolitinib alone, offering a promising new treatment option. Long-term use of gantenerumab may delay Alzheimer's dementia onset in individuals with inherited Alzheimer's, supporting the amyloid hypothesis and paving the way for future prevention strategies. Phase 3 trials demonstrated that povorcitinib, an oral JAK1 inhibitor, significantly improved clinical outcomes in adults with moderate to severe hidradenitis suppurativa, potentially offering a new treatment option. Research linked red meat allergy to bites from additional tick species, expanding the geographic risk area and highlighting the need for clinicians to consider this diagnosis in patients with unexplained allergic symptoms following tick bites.

Jessica Ailani, MD and Carrie Dougherty, MD, FAHS debate initial preventive treatment for migraine and the in-clinic management of status migraine.

Drs. Lebin and Nagle-Yang discuss the pharmacological management of PPD, with a focus on the risks and benefits of selective serotonin reuptake inhibitors (SSRIs) and zuranolone.

Drs. Nagle-Yang and Lebin discuss the barriers to care engagement for patients with PPD, including such factors as stigma, fear of judgement, and access to treatment.

Sarah Nagle-Yang, MD and Lindsay Lebin, MD review the screening, impact, and management of suicide risk in patients with PPD, highlighting effective prevention strategies.

A study suggests GLP-1 receptor agonists may reduce hematologic cancer risk in type 2 diabetes patients by 54% compared to insulin. Two individuals have achieved functional HIV cures through stem cell transplants, offering insights into cure strategies. Additionally, women with dense breasts face double the risk of breast cancer and reduced mammogram accuracy, supporting FDA regulations for breast density notifications and additional screening methods.

An AI system trained on breast ultrasound studies showed promise in reducing false positives and biopsies by over 37% and 28%, respectively, while maintaining sensitivity, potentially aiding clinical decision-making. Second, nirsevimab demonstrated effectiveness in preventing RSV infections and hospitalizations among infants, with protection waning over time but remaining significant. Lastly, breast and colon cancer screening rates in the U.S. have surpassed pre-pandemic levels, but cervical cancer screening rates remain concerningly low, highlighting disparities in access to preventive care.

Drs. McClung and Singer delve into common questions and clinical conundrums encountered in managing osteoporosis and fractures, including calcium use and dental procedures, in patients with osteoporosis.

Drs. Singer and McClung discuss the operationalization of a bisphosphonate “drug holiday” in people treated with this class of osteoporosis medication. They address questions regarding patient selection criteria, duration of the holiday, and strategies for determining when and with what medication treatment should be resumed.